68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan,
instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor.
68Ga-DOTATOC is an improved imaging agent being routinely used in many centers outside the
USA, with better tumor detection than with OctreoScan.